Research programme: antiarrhythmic agents - sanofi-aventis

Drug Profile

Research programme: antiarrhythmic agents - sanofi-aventis

Alternative Names: SAR114646; SAR114646A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antiarrhythmics
  • Mechanism of Action L-type calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Arrhythmias

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Arrhythmias in France (IV)
  • 03 Sep 2008 Pharmacodynamics data from preclinical trials in Arrhythmias presented at the ESC Congress 2008: Annual Congress of the European Society of Cardiology (ESC-2008) ,
  • 01 Jun 2006 Preclinical trials in Arrhythmias in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top